Background: To explore the relationship between CXCR4, CD133 co-expression and clinicopathologicalfeatures as well as prognosis of patients with phase Ⅱ~Ⅲ colon cancer. Materials and
Methods: Forty-nineparaffin-embedded samples of tumor tissue and epithelial tissue adjacent to cancer were collected frompatients with colon cancer undergoing radical surgery in Baotou Cancer Hospital from January, 2010 to June,2011. CXCR4 and CD133 expression was detected using immunohistochemistry and its relationship withclinicopathological features and the 3-year survival rate was analyzed.
Results: In the tumor tissue and colonicepithelial tissue adjacent to cancer, the positive expression rates of CXCR4 were respectively 61.2% (30/49) and8.16% (4/49), while those of CD133 being 36.7% (18/49) and 6.12% (3/49). CXCR4 and CD133 expression intumor tissue was not related to patient age, gender, primary focal sites, tumor size, TNM staging, histological type,tumor infiltration depth and presence or absence of lymphatic metastasis, but CXCR4 and CD133 co-expressionwas associated with TNM staging and lymphatic metastasis. The 3-year survival rate of patients with CXCR4and CD133 co-expression was 27.3% (3/11), and that of the remainderwas 76.3% (29/38), the difference beingsignificant (χ2=7.0206, p=0.0081).
Conclusions: CXCR4 and CD133 co-expression may be a risk factor for poorprognosis of patients with stage Ⅱ~Ⅲ colon cancer.